Abstract

Circulating, cell-free microRNAs (miRNAs) are promising candidate biomarkers, but optimal conditions for processing blood specimens for miRNA measurement remain to be established. Our previous work showed that the majority of plasma miRNAs are likely blood cell-derived. In the course of profiling lung cancer cases versus healthy controls, we observed a broad increase in circulating miRNA levels in cases compared to controls and that higher miRNA expression correlated with higher platelet and particle counts. We therefore hypothesized that the quantity of residual platelets and microparticles remaining after plasma processing might impact miRNA measurements. To systematically investigate this, we subjected matched plasma from healthy individuals to stepwise processing with differential centrifugation and 0.22 µm filtration and performed miRNA profiling. We found a major effect on circulating miRNAs, with the majority (72%) of detectable miRNAs substantially affected by processing alone. Specifically, 10% of miRNAs showed 4–30x variation, 46% showed 30-1,000x variation, and 15% showed >1,000x variation in expression solely from processing. This was predominantly due to platelet contamination, which persisted despite using standard laboratory protocols. Importantly, we show that platelet contamination in archived samples could largely be eliminated by additional centrifugation, even in frozen samples stored for six years. To minimize confounding effects in microRNA biomarker studies, additional steps to limit platelet contamination for circulating miRNA biomarker studies are necessary. We provide specific practical recommendations to help minimize confounding variation attributable to plasma processing and platelet contamination.

Highlights

  • Circulating miRNAs were identified in human plasma and serum in 2008 [1,2,3]

  • We show that standard laboratory protocols for plasma sample processing result in significant differences in platelet content, and that residual platelet contamination is a significant confounding source of circulating miRNAs

  • In our lung cancer biomarker study we found a global increased expression of most miRNAs as well as significant differences in platelet content in cancer cases compared to controls

Read more

Summary

Introduction

Circulating miRNAs were identified in human plasma and serum in 2008 [1,2,3]. Since considerable effort has been directed to the study of circulating miRNAs as biomarkers of diseases, including cancer, cardiovascular, obstetric and rheumatologic conditions [4,5]. Despite excitement about the potential of miRNAs in disease prediction, prognosis and diagnosis, a variety of pre-analytical and analytical considerations need to be addressed to ensure valid scientific inference [6]. These include the establishment of standardized acquisition, processing and storage procedures, as well as the development of assays that are accurate, precise, specific and robust with regard to quantitation of miRNAs. There is growing recognition that pre-analytic variables such as differences in sample processing and handling can be sources of considerable variation in multiplex assays [7]. We investigate the role of processing alone on circulating miRNA measurement

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call